Investing.com-- Australian biotech giant CSL Ltd (ASX:CSL) said on Tuesday it had entered an agreement with Dutch biotech VarmX to develop a new treatment to restore blood coagulation in patients ...

This video provides the latest BMW news and updates, focusing on the M8, upcoming CSL plans, and ECU tuning developments for the N55 and S55 engines. Included in this video: Key insights into BMW M8 ...

CSL will invest up to $760 million in Dutch biotech VarmX, marking the healthcare giant’s first major investment since it announced 3000 job cuts and plans to scale back its global research and ...

VarmX, a Dutch biotech company, has entered a strategic collaboration with CSL. Under the agreement, CSL will fully fund VarmX’s phase 3 trial of its lead candidate, VMX-C001, and retains an exclusive ...

CSL and the private Varmx BV will advance a treatment for patients taking an FXa inhibitor, a chronic anticoagulation therapy. In effect, Varmx’s candidate VMX-C001 is an ‘anti anti coagulation’ ...

CSL Limited on Tuesday told the ASX it had partnered with Dutch biotech firm VarmX to develop a medication against severe bleeding for patients on anticoagulant ...